Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by themagicboxon Jan 24, 2021 7:15pm

161 Views

Post# 32372049

Reverse aging in the brain: PGE2-EP2 link

https://bgr.com/2021/01/22/cognitive-decline-de-age-the-brain-stanford-study/?bgr-partner=flipboard

Scientists singled out the hormones and receptors that advance aging in the brain, PGE1 and EP2 respectively. what are those you ask? oh nothing, just the very hormones and receptors that NSAIDs block, Prostaglandin E1 and Prostaglandin EP2 receptor. But wait, doesnt taking too much NSAIDs causes mucosal lesions, bleeding, peptic ulcer, and inflammation in intestine leading to perforation, strictures in small and large intestines? Why yes they do haha.

Yet another potential avenue for Antibes pipeline to exploit. Enjoy the read.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security